glp 1 cardiovascular risk The effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 and the cardiovascular system

You should always discuss your full medical history with your prescriber to ensure there are no contraindications before starting any new therapy

doses of SAR441255 were studied in lean to overweight individuals and, at the two highest doses tested (80 and 150 ug), fasting blood glucose levels reached a nadir within the first hour [95]

The same 2025 systematic review referenced above found that 35 of 36 studies in the orthopaedic literature were animal or preclinical studies, with no large randomised human trials identified for tendon or ligament recovery specifically [4]

In the phase 3 study, PROTG trial, 516 patients recently diagnosed with T1D (within 12 weeks) were enrolled

If you found this episode helpful, follow Clinical Capsules or leave a quick rating or review